Gonzalo Aranda-Abreu

Prof. Gonzalo Aranda-Abreu

Universidad Veracruzana, Xalapa, Veracruz, Mexico
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2022 in NeuroSci
Verified
Journal Article
Open access
PDF file
SLSandra Yasbeth Lara
Sandra Yasbeth Lara
ÁFÁngel de Jesús Laureani Fierro
Ángel de Jesús Laureani Fierro
GAGonzalo Aranda-Abreu
Gonzalo Aranda-Abreu
María Rebeca Toledo-CardenasMaría Rebeca Toledo-Cardenas
María Rebeca Toledo-Cardenas
Luis I. GarcíaLuis I. García
Luis I. García
CECESAR ANTONIO PEREZ ESTUDILLO
CESAR ANTONIO PEREZ ESTUDILLO
For years, the biochemical processes that are triggered by harmful and non-harmful stimuli at the central nervous system level have been extensively studied by the scientific community through numerous techniques and animal models. For example, one of these techniques is the use of immediate expression genes, which is a useful, accessible, and reliable method for observing and quantifying cell activation. It has been shown that both the c-fos gene and its protein c-Fos have rapid activation after stimulus, with the length of time that they remain active depending on the type of stimulus and the activation time depending on the stimulus and the structure studied. Fos requires the participation of other genes (such as c-jun) for its expression (during hetero-dimer forming). c-Fos dimerizes with c-Jun protein to form factor AP-1, which promotes the transcription of various genes. The production and removal of c-Fos is part of cellular homeostasis, but its overexpression results in increased cell proliferation. Although Fos has been used as a marker of cellular activity since the 1990s, which molecular mechanism participates in the regulation of the expression of this protein is still unknown because the gene and the protein are not specific to neurons or glial cells. For these reasons, this work has the objective of gathering information about this protein and its use in neuroscience.

1 July 2020 in Medical Hypotheses
Verified
Journal Article
Closed access
GAGonzalo Aranda-Abreu
Gonzalo Aranda-Abreu
MHMaria Elena Hernandez-Aguilar
Maria Elena Hernandez-Aguilar
Deissy Herrera-CovarrubiasDeissy Herrera-Covarrubias
Deissy Herrera-Covarrubias
FRFausto Rojas-Durán
Fausto Rojas-Durán

1 October 2020 in Archives of Medical Research
Verified
Journal Article
Closed access
RARamiro Araújo
Ramiro Araújo
JAJosé Dolores Aranda-Martínez
José Dolores Aranda-Martínez
GAGonzalo Aranda-Abreu
Gonzalo Aranda-Abreu

Verified
Journal Article
Open access
PDF file
CRCARLOS CASTILLO RANGEL
CARLOS CASTILLO RANGEL
Gerardo MarínGerardo Marín
Gerardo Marín
KHKarla Aketzalli Hernández-Contreras
Karla Aketzalli Hernández-Contreras
MVMicheel Merari Vichi-Ramirez
Micheel Merari Vichi-Ramirez
Cristofer Zarate-CalderonCristofer Zarate-Calderon
Cristofer Zarate-Calderon
Luis I. GarcíaLuis I. García
Luis I. García
Parkinson’s disease is a neurodegenerative disease whose progression and clinical characteristics have a close bidirectional and multilevel relationship with the process of neuroinflammation. In this context, it is necessary to understand the mechanisms involved in this neuroinflammation–PD link. This systematic search was, hereby, conducted with a focus on the four levels where alterations associated with neuroinflammation in PD have been described (genetic, cellular, histopathological and clinical-behavioral) by consulting the PubMed, Google Scholar, Scielo and Redalyc search engines, including clinical studies, review articles, book chapters and case studies. Initially, 585,772 articles were included, and, after applying the inclusion and exclusion criteria, 84 articles were obtained that contained information about the multilevel association of neuroinflammation with alterations in gene, molecular, cellular, tissue and neuroanatomical expression as well as clinical-behavioral manifestations in PD.

10 October 2020 in Pharmacological Reports
Verified
Journal Article
Open access
PDF file
GAGonzalo Aranda-Abreu
Gonzalo Aranda-Abreu
JAJosé D. Aranda-Martínez
José D. Aranda-Martínez
RARamiro Araújo
Ramiro Araújo
MHMaria Elena Hernandez-Aguilar
Maria Elena Hernandez-Aguilar
Deissy Herrera-CovarrubiasDeissy Herrera-Covarrubias
Deissy Herrera-Covarrubias
FRFausto Rojas-Durán
Fausto Rojas-Durán
Background We conducted an observational study of 15 patients from a Southeastern area of Mexico with symptoms compatible with SARS-Cov-2, which were treated with the antiviral amantadine. Methodology In this study, data were collected from 15 individuals with clinical symptoms of COVID-19 infection, which were treated on an ambulatory basis with 100 mg of amantadine for a period of 14 days. Results This drug demonstrated its effectiveness, as patients recovered successfully with this treatment without the necessity of attending a hospital to use mechanical ventilation. All patients developed IgG antibodies to SARS-Cov-2. Conclusion Amantadine can be used as a viable and cost-effective alternative for treating people with severe acute respiratory syndrome (SARS-Cov-2) on an ambulatory basis, while the vaccine is not available.

17 May 2006 in Reproductive Biology and Endocrinology
Verified
Journal Article
Open access
MHMaria Elena Hernandez-Aguilar
Maria Elena Hernandez-Aguilar
ASAbraham Soto-Cid
Abraham Soto-Cid
FRFausto Rojas-Durán
Fausto Rojas-Durán
LPLuz I Pascual
Luz I Pascual
GAGonzalo Aranda-Abreu
Gonzalo Aranda-Abreu
Jorge ManzoJorge Manzo
Jorge Manzo
The prostate is a key gland in the sexual physiology of male mammals. Its sensitivity to steroid hormones is widely known, but its response to prolactin is still poorly known. Previous studies have shown a correlation between sexual behaviour, prolactin release and prostate physiology. Thus, here we used the sexual behaviour of male rats as a model for studying this correlation. Hence, we developed experimental paradigms to determine the influence of prolactin on sexual behaviour and prostate organization of male rats. In addition to sexual behaviour recordings, we developed the ELISA procedure to quantify the serum level of prolactin, and the hematoxilin-eosin technique for analysis of the histological organization of the prostate. Also, different experimental manipulations were carried out; they included pituitary grafts, and haloperidol and ovine prolactin treatments. Data were analyzed with a One way ANOVA followed by post hoc Dunnet test if required. Data showed that male prolactin has a basal level with two peaks at the light-dark-light transitions. Consecutive ejaculations increased serum prolactin after the first ejaculation, which reached the highest level after the second, and started to decrease after the third ejaculation. These normal levels of prolactin did not induce any change at the prostate tissue. However, treatments for constant elevations of serum prolactin decreased sexual potency and increased the weight of the gland, the alveoli area and the epithelial cell height. Treatments for transient elevation of serum prolactin did not affect the sexual behaviour of males, but triggered these significant effects mainly at the ventral prostate. The prostate is a sexual gland that responds to prolactin. Mating-induced prolactin release is required during sexual encounters to activate the epithelial cells in the gland. Here we saw a precise mechanism controlling the release of prolactin during ejaculations that avoid the detrimental effects produced by constant levels. However, we showed that minor elevations of prolactin which do not affect the sexual behaviour of males, produced significant changes at the prostate epithelium that could account for triggering the development of hyperplasia or cancer. Thus, it is suggested that minute elevations of serum prolactin in healthy subjects are at the etiology of prostate abnormal growth.